Deltex Medical Group (DEMG)

Sector:

Health Care

Index:

FTSE AIM All-Share

0.080p
   
  • Change Today:
      0.005p
  • 52 Week High: 0.18p
  • 52 Week Low: 0.073p
  • Currency: UK Pounds
  • Shares Issued: 1,896.03m
  • Volume: 4,367,266
  • Market Cap: £1.52m
  • RiskGrade: 344

Deltex Medical Group launches 'TrueVue' haemodynamic monitoring system

By Josh White

Date: Tuesday 24 Oct 2017

LONDON (ShareCast) - (ShareCast News) - Oesophageal doppler monitoring company Deltex Medical Group announced the launch of a "revolutionary concept" in advanced haemodynamic monitoring on Tuesday - the 'TrueVue' system.
The AIM-traded firm said the TrueVue system comprised three "distinct best-in-class" advanced haemodynamic monitoring technologies on a single platform.

They included the TrueVue Doppler - a "high-end" ODM technology providing beat-to-beat imaging of cardiac output for monitoring sedated patients and easy calibration and recalibration of arterial pressure cardiac output.

It also included TrueVue Impedance - a non-invasive, high definition impedance cardiography for monitoring awake patients, both mobile and immobile.

The final monitoring technology was TrueVue Loops,, described as unique real-time biomarkers for early detection of hypo- and hyper-volaemia, hypo- and hyper-tension and real-time display of responses to treatment.

Deltex said the TrueVue system was being featured at its booth at Anesthesiology 2017, the annual meeting of the American Society of Anesthesiologists in Boston, Massachusetts.

It added that use of TrueVue Impedance in the US remained subject to FDA approval, with the submission made but not yet granted.

"The launch of the TrueVue system on the CardioQ-ODM+ platform is an exciting development for the company," said Deltex chief executive Ewan Phillips.

"It means we will now be marketing the world's first haemodynamic monitoring system which can be used across the whole patient pathway from awake, mobile outpatients of all ages through to sedated, critical care patients."

Phillips said the TrueVue system could be used by trainee staff, in non-critical situations, through to experienced specialists.

"It will also broaden the company's addressable market and positions us to supply hospitals with all their haemodynamic monitoring requirements on a single platform."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

DEMG Market Data

Currency UK Pounds
Share Price 0.080p
Change Today 0.005p
% Change 6.67 %
52 Week High 0.18p
52 Week Low 0.073p
Volume 4,367,266
Shares Issued 1,896.03m
Market Cap £1.52m
RiskGrade 344

DEMG Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
25.21% above the market average25.21% above the market average25.21% above the market average25.21% above the market average25.21% above the market average
94.29% above the sector average94.29% above the sector average94.29% above the sector average94.29% above the sector average94.29% above the sector average
Price Trend
84.1% below the market average84.1% below the market average84.1% below the market average84.1% below the market average84.1% below the market average
67.57% below the sector average67.57% below the sector average67.57% below the sector average67.57% below the sector average67.57% below the sector average
Income Not Available
Growth
59.88% below the market average59.88% below the market average59.88% below the market average59.88% below the market average59.88% below the market average
72.22% below the sector average72.22% below the sector average72.22% below the sector average72.22% below the sector average72.22% below the sector average

DEMG Dividends

No dividends found

Trades for 21-Nov-2024

Time Volume / Share Price
13:20 1,400,000 @ 0.084p
12:55 250,000 @ 0.084p
12:26 1,000,000 @ 0.084p
12:14 100,000 @ 0.086p
10:34 250,000 @ 0.080p

DEMG Key Personnel

Chair Nigel J Keen
CEO Andy Mears
Finance Director Natalie Wettler

Top of Page